Glucose-methanol based fed batch fermentation for the production of recombinant human interferon gamma (rhIFN-γ) and evaluation of its antitumor potential.
Squamous cell carcinoma (SCC) is non-melanoma skin cancer, which is very common in patients having T-cell immunosuppressant drugs. Anti-cancerous agents such as cytokines shown effective response on SCC. Human interferon-gamma (hIFN-γ) a type II cytokines are having potent antiproliferative, and immunomodulatory effects. In the current study, the fed-batch cultivation of recombinant Pichia pastoris was carried out, and its effect on cell biomass production, recombinant human interferon-gamma (rhIFN-γ) production, and the overflow metabolites was estimated. Pichia pastoris GS115 strain co-expressed with 6-phosphogluconolactonase (SOL3) and ribulose-phosphate 3-epimerase (RPE1) gene (GS115/rhIFN-γ/SR) resulted in 60 mg L-1 of rhIFN-γ production which was two-fold higher as compared to the production from GS115/rhIFN-γ strain. The anti-proliferative potential of rhIFN-γ was examined on the human squamous carcinoma (A431) cell lines. Cells treated with 80 ng mL-1 of rhIFN-γ exhibited 50% growth inhibition by enhancing the production of intracellular reactive oxygen species (ROS) levels and disrupting membrane integrity. Our findings highlight a state of art process development strategy for the high-level production of rhIFN-γ and its potential application as a therapeutic drug in squamous cell carcinoma therapy. This article is protected by copyright. All rights reserved.